2022 World Conference on Lung Cancer (ePosters)-EP16.02-017. Predictive Value of Peripheral Blood Immune Cell Profiling in EGFR-T790M Mutant Lung Adenocarcinoma

Pdf Summary

This research poster presentation discusses the predictive value of peripheral blood immune cell profiling in patients with EGFR-T790M mutant lung adenocarcinoma (LUAD). The study enrolled a total of 70 patients with LUAD, and 35.71% of them had underlying diseases such as hypertension, diabetes mellitus, abnormal liver function, coronary heart disease, cerebral thrombosis, gastric ulcer, and psoriasis.<br /><br />The study found that the levels of CD244CD8 T cells and CD244 NK cells in peripheral blood were significantly lower in T790M-positive patients compared to T790M-negative patients. There was no statistical difference in the expression of immune checkpoints on CD4 T cells and B cells between the two groups.<br /><br />The differences in peripheral immune cell profiles between patients with progressive and advanced tumors were mainly focused on T cells and NK cells. Patients with advanced T790M-negative disease had reduced levels of T cells, CD272CD4 T cells, CD272CD8 T cells, CD244CD8 T cells, CD244 NK cells, and CD272 NK cells compared to patients with progressive stages. Patients with advanced T790M-positive disease had a reduced CD4/CD8 ratio and higher levels of T-bet NK cells.<br /><br />The study also found that the levels of peripheral blood immune cells and the expression of immune checkpoints were more affected by the degree of tumor progression in T790M-negative patients than in T790M-positive patients.<br /><br />Additionally, the study showed that the levels of peripheral blood immune cells before treatment with osimertinib could predict the outcome of the treatment. Patients with good efficacy after osimertinib treatment had higher levels of B cells, effector CD4 T cells, and CD4/CD8 ratio before treatment.<br /><br />In conclusion, peripheral blood immune cell profiling may have predictive value in determining the efficacy of osimertinib treatment in patients with EGFR-T790M mutant LUAD. The study provides insights into the potential role of immune cells in lung cancer and highlights the importance of considering immune cell profiles in personalized treatment approaches.

Asset Subtitle

Yutao Liu

Meta Tag

Speaker Yutao Liu

Topic Tumour Biology and Biomarkers - Minimally Invasive Biomarkers

Keywords

predictive value

peripheral blood immune cell profiling

EGFR-T790M mutant lung adenocarcinoma

LUAD

underlying diseases

CD244CD8 T cells

CD244 NK cells

immune checkpoints

progressive and advanced tumors

osimertinib treatment